September 2017 | Oncology Business News®

Why Oncology Can Be a Tough Sell in Maine

September 20, 2017

Chimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.

PROs Save Money, Lives, and Improve QoL

August 09, 2017

Despite improved outcomes with new treatment and targeted therapies, patients with cancer continue to be afflicted by distressing symptoms and serious toxicities, which affect daily functioning and quality of life.